A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Phase 1
88
about 2.8 years
45–85
7 sites in CA, FL, GA +2
About this study
This trial is testing the safety and tolerability of a drug called LY4006895. Part A will give healthy people a single dose, while Part B will give participants with early Alzheimer's disease multiple doses. Blood tests will be done to see how much of the drug gets into the body and how long it stays there.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY4006895
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4006895, PK: Maximum Concentration (Cmax) of LY4006895
Neurology